Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from MicroPort NeuroTech Limited ( (HK:2172) ).
MicroPort NeuroScientific Corporation has published an updated list of its directors and detailed their respective roles across five key board committees, underscoring its governance and oversight framework. The announcement confirms the current board lineup, with Dr. Zhang Jie serving as non-executive chairman and a mix of executive, non-executive and independent non-executive directors allocated to lead or sit on the audit, remuneration, nomination, strategic and commercialization committees, signaling a structured approach to strategic decision-making and commercialization efforts as the company executes its business strategy.
The most recent analyst rating on (HK:2172) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.
More about MicroPort NeuroTech Limited
MicroPort NeuroScientific Corporation is a Cayman Islands–incorporated medical technology company listed in Hong Kong that focuses on neuro-related healthcare solutions. The company operates under a board structure comprising executive, non-executive and independent non-executive directors who oversee corporate governance through specialized committees covering audit, remuneration, nomination, strategic planning and commercialization.
Average Trading Volume: 2,442,878
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.23B
For detailed information about 2172 stock, go to TipRanks’ Stock Analysis page.